Member Info for Fadec92

I’m sure this is SAR chat site, the risk is there that they don’t RTO, and remains a shell they have tryed 3 times to list in Singapore offcourse you know that! Lol..

Burningspear haven’t you got a parrot to bore to tears somewhere in your house!

The Hemp business for CBD is in the hands of the old District 8 management at the facility in Debeque western Colorado where the product is being grown and used to grow Cannabis plants so the involvement with Highlands is making deals and bringing the sales in collaboration of skills, the placing is paying for the costs that took place recently so the oil and gas line is separate other that the gas they have that grows the Hemp is proven to increase the growth factor of cannabis plants by 30% and that is sourced from an organic N2 gas well found in western Kansas that is enriched with Hydrogen that is produced from a PSA Pressure swing absorbing unit/facility there!

Dave would not say that the wells will not decline (he knows better after visits to wellpad) because in time it’s obvious that all wells decline especially unconventional wells so you are just plain making stuff up, causing trouble and targeting a person (share holder) with abuse!

The company clearly states the situation of the wells production so people don’t have to listen to the drivel in your victimizing posts!

In True Troll Style blaming other share holders (Dave) when in the latest company RNS it states :-

“Combined oil production from the eight producing wells is currently approximately 2,700 Bopd and combined gas production is currently approximately 4,000 Mcfpd. Highlands' operating partner continues to proceed with its conservative production strategy. Five of the new wells are being operated on a limited choke size of 25/64th inch with the sixth well at 29/64th inch.

The limited choke size is based on a considered methodology focused on maintaining well pressure and extending the well lives. It is anticipated that the chokes will be opened further in the coming weeks with the objective of maintaining a steady production at around 10% above current levels.”

“Professor de Bono has both a private and an NHS practice at The Royal Marsden”

So being that the SRA737 trials have majored at the Royal Marsden in London and with Professor Johanna de Bono having developed the Olaparib PARP inhibitor with AstraZeneca and Merck, than he would be the best man to Direct the next new wave of development of the SRA737 combination with Niraparib the PARP inhibitor!

He was involved in the development of many novel agents, many of which are now approved drugs namely “Olaparib”

“Olaparib (AZD-2281, MK-7339 trade name Lynparza) is an FDA-approved targeted therapy for cancer. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.”

https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/professor-johann-sebastian-de-bono

“Sierra has designed clinical trials and has conducted preclinical research evaluating SRA737 in combination with other DDR-targeted agents, including poly ADP-ribose polymerase (PARP) inhibitors, as well as with immuno-oncology therapeutics, that could potentially guide the next planned wave of clinical development for this asset.”

Janssen has agreed to supply the PARP inhibitor niraparib, facilitating the potential initiation of a PARP inhibitor combination trial with SRA737 for the treatment of prostate cancer. :-

http://www.sareum.com/news/press-releases-and-news/2019/sareum-notes-sierra-oncology-q1-2019-results/

More like Market are thinking off a SRRA raise to pay for further evaluation!

June 1st - Poster presentations.

SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials.

Sierra to hold Analyst & Investor Event at 6:00 am CT on June 3rd featuring distinguished oncologists :-

Professor Johann de Bono and Dr. Rebecca Kristeleit

June 3 - 6:00 am CT to review the clinical findings from SRA737 Phase 1/2 Monotherapy and SRA737+LDG trials presented at ASCO and potential next steps in the development strategy for SRA737.

And

June 5th - Overview at the Jefferies Global Healthcare Conference in New York

Conclusions: The combination of LDG and SRA737 has been well tolerated. This first-in-human clinical study provides proof-of-concept that sub-therapeutic LDG effectively potentiates SRA737. This novel replication stress-targeted therapy warrants further evaluation in genetically pre-defined solid tumors. Clinical trial information:

http://abstracts.asco.org/239/AbstView_239_255379.html

http://investor.sierraoncology.com/2019-05-28-Sierra-Oncology-to-Present-Momelotinib-and-SRA737-Overview-at-the-Jefferies-Global-Healthcare-Conference-in-New-York?platform=hootsuite

Missed this tweet from Robin Davidson 10 days old!

Pfizer recently disclosed a P2 study of the TYK2/JAK1 inhibitor with potential additional benefit of dual approach of high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3) which Sareum has only other dual TYK2/JAK1!

https://twitter.com/robindavison2/status/1129045198489686018?s=21

Thought that too Aber, probably will change from deramping to euphoric in a very short space of time!

I think a milestone payment will get payed after ASCO presentation, lots of research pointing too good results with combinations, good reason for me too top up, safety data good and dosing with statements like :-

“preclinical data showing “profound synergy” for the triple combination of the CHK1 inhibitor SRA737 in combination with low-dose gemcitabine (LDG) and anti-PD-L1 immunotherapy in a mouse model of small cell lung cancer (SCLC)”

Also

“In the study presented, the three agent combination showed durable tumour regression in 10/10 animals at the end of the 21-day treatment period with 8/10 showing sustained complete response after a further 39 days without further treatment“

“SCLC, which accounts for c15% of all lung cancer cases, is one of four subsidiary indications being pursued by Sierra in the ongoing study of SRA737 in combination with LDG”

“£88m in milestones to come that’s dependent on predetermined milestone triggers which are not disclosed at this stage and Royalty’s on sales between 2-3%.“

It’s different it’s not a Tyk2 inhibitor a member of the Janus Kinase family, two of the targets are the same in psoriasis and lupus though!

https://en.m.wikipedia.org/wiki/BET_inhibitor

Thanks Biotech good find, there’s also two other links on the site which proves useful!

https://quoteddata.com/2019/04/sareum-notes-strong-preclinical-sclc-data-sra737-aacr/

https://quoteddata.com/2019/04/sareum-benefit-lilly-decision-competitor-product/

https://www.healtheuropa.eu/oxygen-eliminate-types-of-cancer-cells/87889/

Direct Link - https://vimeo.com/329309219

Not sure if the Video with Dr Sen has been posted before!

Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas

Efficacy and immune correlates of the SRA737 plus LDG (Low Dose gemcitabine) regimen in combination with anti-PD-L1 in an SCLC (Small Cell Lung Cancer) model

SCLC Accounts for 15% of all Lung Cancers cases in the US.

Dr Triparna Sen speaks to ecancer at the 2019 American Association for Cancer Research

(AACR) meeting about results from a study looking at the efficacy and correlates of immunity of the combination treatment involving CHK1 inhibitor SRA737 plus low dose gemcitabine with anti-PDL1 in a model of small cell lung cancer (SCLC).

She explains that SCLC is very good at hiding itself from the immune system causing most of the immunotherapy drugs so far to have modest benefit.

Dr Sen reports that this combination with immune checkpoint blockade and DNA damage repair completely regressed tumours in mouse models.

https://ecancer.org/video/7768/efficacy-and-immune-correlates-of-the-sra737-plus-ldg-regimen-in-combination-with-anti-pd-l1-in-an-sclc-model.php

https://www.proactiveinvestors.co.uk/companies/news/217748/sareums-flagship-chk1-inhibitor-shows-serious-lung-cancer-potential-in-mouse-models-217748.html

Oh Discussion are going on definitely for Tyk2 SDC-1801 and SDC-1802 as said by Tim in the interview!

“Keeping the interested party’s informed and when they have sufficient data for their needs then look what a licensing deal can look like”

Also said that

“To Look to license between now or certainly after pre-clinical safety study’s through to in the clinic”

Also £88m in milestones to come that’s dependent on predetermined milestone triggers which are not disclosed at this stage and Royalty’s on sales between 2-3%.“

You would think that some milestones would be payed after the ASCO presentations by SRRA on the phase 1/2 study results, we have just had the Initial Safety Abstract Disclosures which were good!

Sareum's Tim Mitchell looks ahead to critical Phase II data from flagship Chk1 inhibitor

https://www.proactiveinvestors.co.uk/companies/stocktube/12541/sareum-s-tim-mitchell-looks-ahead-to-critical-phase-ii-data-from-flagship-chk1-inhibitor-12541.html

Looks like mm’s happy to take back up, would be good if we could get some volume, should be better volume after the early safety data from SRRA being well tolerated, happy to see more data coming soon with SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations!

So that’s the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago to discuss these clinical findings and potential next steps in the development strategy for SRA737.

Presentation by two distinguished oncologists:

Professor Johann de Bono,

Regius Professor of Cancer Research, Head of the Division of Clinical Studies and Professor in Experimental Cancer Medicine at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, will discuss the critical role of Chk1 in tumor cell survival during replication stress (RS), as well as describe potential opportunities to combine SRA737 with other therapeutic modalities including PARP inhibitors and immunotherapy agents.

Dr. Rebecca Kristeleit,

Clinical Senior Lecturer and Honorary Consultant Medical Oncologist at University College London (UCL) Cancer Institute & UCLH Dept. of Oncology, a leading expert in gynecological malignancies, will discuss her clinical experience with SRA737+LDG, and potential development opportunities for this novel combination in the treatment of anogenital cancers.

I Re-tweeted the proactive tweet from Sareum earlier about that as described here that Lilly’s Prexasertib discontinued and Roche’s stopped with safety issues and Sareums improved safety with an excellent result in that respect, plus it’s the only chk1, Sareum liked the tweet so are ok with other people shouting about this good result!

https://twitter.com/fadec92/status/1128951206712356866?s=21